TFF Pharmaceuticals (TFF Pharmaceuticals) 3-Year EBITDA Growth Rate : 19.50% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is TFF Pharmaceuticals 3-Year EBITDA Growth Rate?

TFF Pharmaceuticals's EBITDA per Share for the three months ended in Dec. 2023 was $-2.21.

During the past 3 years, the average EBITDA Per Share Growth Rate was 19.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of TFF Pharmaceuticals was 19.50% per year. The lowest was -350.10% per year. And the median was 15.50% per year.

Competitive Comparison of TFF Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, TFF Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TFF Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TFF Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where TFF Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

TFF Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

TFF Pharmaceuticals (NAS:TFFP) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

TFF Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of TFF Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

TFF Pharmaceuticals (TFF Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TFF Pharmaceuticals Inc (NAS:TFFP) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.tffpharma.com

TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

Executives

Carlson Capital L P	10 percent owner	2100 MCKINNEY AVE, STE 1900, DALLAS TX 75201
Clint Duane Carlson	10 percent owner	2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Zamaneh Mikhak	officer: Chief Medical Officer	1751 RIVER RUN, SUITE 400, C/O TFF PHARMACEUTICALS, INC., FORT WORTH TX 76107
Robert S Mills	director	8 MISTY BROOK LANE, NEW FAIRFIELD CT 06812
Kirk Allen Coleman	officer: CFO, Secretary, and Treasurer	2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
Stephen Rocamboli	director	C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Asgard Investment Corp. Ii	10 percent owner	2100 MCKINNEY AVENUE, SUITE 1800, DALLAS TX 75201
Double Black Diamond Offshore Ltd	10 percent owner	CITCO FUND SERVICES, 89 NEXUS WAY, P.O. BOX 31106, CAMANA BAY E9 KY-1205
Harlan F Weisman	director	C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Brandi Roberts	director	12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Randy H Thurman	director	222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Glenn R. Mattes	director, officer: President and CEO	200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Malcolm Fairbairn	director	C/O ASCEND CAPITAL, LLC, 4 ORINDA WAY, SUITE 200-C, ORINDA CA 94563
Lung Therapeutics, Inc.	10 percent owner	P.O. BOX 150183, AUSTIN TX 78715